Hanchor-KY
英屬開曼群島商漢康生技(股)公司
Hanchor-KY is a Taiwan TWSE-listed biotechnology company; its most advanced asset is HCB101 (Phase 1 / Phase 2; recruiting, HNSCC), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| HCB101 | — | Phase 1 / Phase 2; recruiting | HNSCC | Taiwan | 2026-07-06 | Trial registry |
| HCB301 | — | Phase 1; recruiting | Advanced Solid Tumor; Refractory Hodgkin Lymphoma | China, Taiwan, United States | 2026-04-13 | Trial registry |
| HCB303 | — | Phase 1; not yet recruiting | Advanced Malignancies | — | 2026-10-05 | Trial registry |
Key events
No verified events in the past twelve months.
Related Drugnews articles
No related articles in this language.